NKTR

Nektar Therapeutics

$63.86 -1.57%

Recent alerts on NKTR

All signals →

News What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch

Insider trade Sale by Zalevsky Jonathan (Chief R&D Officer)

Insider trade Sale by ROBIN HOWARD W (President & CEO)

News Why Nektar Therapeutics Stock Popped 6% on Friday

News Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top

News Why Nektar Therapeutics Stock Rocked it Today

SEC filing NKTR Enters $150M ATM Equity Offering, Names Linda Rubinstein Interim CFO Replacing Sandra Gardiner

News Nektar expects $800M-$825M cash at end of 2026 while targeting REZPEG BLA in 2029

SEC filing NKTR Prices $325M Upsized Offering, 3.53M Shares at $92, Net Proceeds for R&D, Manufacturing

News Nektar Therapeutics prices upsized $325M public offering at $92.00 per share

SEC filing NKTR Reports $741.7M Cash & Marketable Securities as of Apr 1, 2026

News Nektar posts 52-week data from mid-stage trial for hair loss therapy

SEC filing NKTR Reports 29%/31% SALT≤20 Responders, 94% Completion, Favorable Safety in REZOLVE-AA Extension

News Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B

News Nektar Therapeutics jumps on Q4 results

News Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters Phase III in atopic dermatitis

SEC filing NKTR Reports $21.8M Q4 Rev, $55.2M FY Rev, $164.1M Net Loss, $8.66 Non-GAAP EPS, $245.8M Cash, $432M Offering Proceeds, Phase 3 June Start

Insider trade Sale by Jonathan Zalevsky

News Nektar’s stock rises 51% on Phase II Rezpeg AD maintenance win

News Nektar Therapeutics stock pops on $300M equity offering

News Top Quant rated bullish small cap stocks among companies with high short interest

Scanner Unusual buy pressure (9.3x avg, 66% up-volume, +43.2% intraday, above VWAP)

News Nektar eyes late-stage program for eczema therapy after positive mid-stage data

SEC filing NKTR Announces REZOLVE-AD Maintenance Data: EASI-75 Responses at 71%, EASI-90 at 80%, vIGA-AD 0/1 at 85%, EASI-100 Response Rates Up to 5-Fold Increase

News INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

Get push alerts for NKTR

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS